Fig. 4: Animal experiment and analysis between the HC group and the HCC group.
From: Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma
a The process of animal experiment. 6-week-old C57BL/6J male mice were acclimated for one week. On day 0, tumor cells were injected. From day −7 to day 2, AVMN (1 mg/mL ampicillin, 1 mg/mL neomycin, 1 mg/mL metronidazole, and 0.5 mg /mL vancomycin, for drink) was administered. From day 4 to day 16, Fecal microbiota transplantation (FMT, 50 mg per mouse), Bifidobacterium (Bif, 1–2 × 108 CFU), isobutyrate (150 mM for drink), and/or αPD-1 therapy (200 μg per mouse) were conducted. On day 18, the mice were sacrificed for sampling. b–d The changes in the tumor volume among all groups. n = 8 per group. e Tumor tissues stained with H&E. f Tumor tissues stained with Ki67. g–i The changes in the IFN-γ value in the serum among all groups. n = 8 per group. One-way ANOVA test was used.
